Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RO 7795081

Next Previous
Drug Profile

RO 7795081

Alternative Names: CT-996; RG-6652; RO-7795081

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Carmot Therapeutics
  • Developer Carmot Therapeutics; Roche
  • Class Antihyperglycaemics; Obesity therapies; Small molecules
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 31 Mar 2026 Hoffmann-La Roche plans a phase I trial in Obesity (In volunteers) (PO) in march 2026 (NCT07499050)
  • 23 Feb 2026 Roche initiates enrolment in a phase I trial Obesity and Type 2 diabetes mellitus (In volunteers) in Netherlands (PO) (CTIS2025-524210-28-00)
  • 01 Dec 2025 Roche plans to file a regulatory application of RO 7795081 in Obesity and Type 2 diabetes mellitus in 2028 or beyond (Roche pipeline, December 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top